myos corp (MYOS) Key Developments
MYOS Corporation's Preclinical Study of Fortetropin's Mechanism of Action Demonstrate Regulatory Effects on Three Key Muscle Health Pathways
Jan 22 15
MYOS Corporation announced that its mechanism of action studies have identified three key molecular signaling pathways in which Fortetropin™ exhibits regulatory effects. In addition to reducing serum myostatin levels, MYOS recently completed a preclinical mechanism of action study that demonstrated Fortetropin's activity in mTOR and Ubiquitin, two other crucial signaling pathways in the growth and maintenance of healthy muscle. Myostatin is a naturally occurring regulatory protein which prevents muscle growth. Myostatin serum levels increase as people age which can lead to age-related muscle loss or sarcopenia. Fortetropin's ability to reduce serum myostatin levels has been clinically proven. Regulation of myostatin may be a key element in the treatment of sarcopenia. In addition to myostatin regulation, MYOS' preclinical data also showed that Fortetropin up-regulates the mTOR regulatory pathway. The mTOR pathway is responsible for production of a protein kinase related to cell growth and proliferation that increases skeletal muscle mass. Up-regulation of the mTOR pathway is important in preventing muscle atrophy. Fortetropin's ability to affect the mTOR pathway may have a significant impact in treating patients suffering from degenerative muscle diseases and suggests that Fortetropin-based products may help slow muscle loss secondary to immobility and denervation. Finally, the Company's recent animal model study demonstrated that Fortetropin acts to reduce the synthesis of proteins in the Ubiquitin pathway, a highly selective, tightly regulated system that serves to activate muscle breakdown. Over-production in the Ubiquitin pathway is responsible for muscle degradation. Fortetropin's ability to regulate production in the Ubiquitin pathway may have significant implications for repairing age-related muscle loss and for patients suffering from chronic diseases causing cachexia.
MYOS Corporation Appoints EisnerAmper LLP as Independent Registered Public Accounting Firm
Dec 23 14
MYOS Corporation Company held its annual meeting of stockholders on December 22, 2014 ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014.
MYOS Corporation Approves Amendment to Articles of Incorporation
Dec 23 14
MYOS Corporation held its annual meeting of stockholders on December 22, 2014, approved a Certificate of amendment to its articles of incorporation, as amended (the 'Articles of Incorporation') with the Secretary of State of the State of Nevada to effect an increase in the aggregate number of authorized shares of common stock by 2,000,000 shares to 8,000,000 shares.
MYOS Corporation Presents at 8th Annual OneMedForum 2015, Jan-13-2015 10:30 AM
Dec 19 14
MYOS Corporation Presents at 8th Annual OneMedForum 2015, Jan-13-2015 10:30 AM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States. Speakers: Robert C. Ashton, Chief Medical Officer and Member of the Scientific Advisory Board.
MYOS Corp. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 14 14
MYOS Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's net sales were approximately $107,000 compared to $918,000 a year ago. Loss from operations was $2,177,000 compared to $782,000 a year ago. Net loss and comprehensive income was $2,177,000 compared to $781,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.75 compared to $0.35 a year ago. Non-GAAP, net loss was $1,625,000 compared to $454,000 for a year ago. Non-GAAP basic and diluted net loss per share was $0.56 compared to $0.20 a year ago.
For the nine months, the company's net sales were approximately $3,332,000 compared to $1,910,000 a year ago. Loss from operations was $3,601,000 compared to $2,858,000 a year ago. Net loss and comprehensive income was $3,599,000 compared to $2,854,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $1.28 compared to $1.29 a year ago. Non-GAAP, net loss was $2,267,000 compared to $1,789,000 for a year ago. Non-GAAP basic and diluted net loss per share was $0.81 compared to $0.81 a year ago.